Liquidia Corporation

We are deeply passionate and committed to the discovery, engineering, and development required to bring novel therapies to patients who need them most, and to the healthcare providers who care for them. Our current drive is toward improving the treatment of pulmonary arterial hypertension (PAH).

We will continue to combine our proprietary, innovative PRINT Technology with new and established medications, offering the potential for both better precision and improved clinical outcomes.

News Releases

MAY 13 2021

Liquidia Reports First Quarter 2021 Financial Results and Provides Corporate Update

- Doubled the market opportunity for Treprostinil Injection by adding subcutaneous delivery - Resubmitted New Drug Application for LIQ861 (treprostinil) Inhalation Powder - Improved financial position with private placement and access to new credit facility - Company to host webcast and conference
MAY 10 2021

Liquidia Resubmits New Drug Application for LIQ861 (treprostinil) Inhalation Powder for the Treatment of Pulmonary Arterial Hypertension

MORRISVILLE, N.C. , May 10, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that on May 7, 2021 , it resubmitted its New Drug Application (NDA) for LIQ861 for the treatment of pulmonary arterial hypertension (PAH). The U.S.

btn News